This story is from the CurrentWire archive. Coverage details reflect the last time it was updated.
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026
Emerge Phase 3 study podium poster to be featured in “Latest Discoveries & Emerging Trends in MDD” session New epidemiological research on risks associated with anxiety and depression plus five posters across clinical program NEW YORK — Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics […]
Financial Post
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from Financial Post.
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
Financial Post (financialpost.com), a Tier B publisher, filed this report on . CurrentWire published this page 22 minutes later, on .
Filed under Politics · United States · News. Topics extracted from this report, with other live CurrentWire stories mentioning each: Congress (14), New York (13), Present Topline Data (none), Voyage Trials Across Major Depressive Disorder (none), Generalized Anxiety Disorder (none), Psych Congress (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.